Biogen skyrockets following positive Alzheimer's study results, Eli Lilly and MorphoSys jump in concert Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Biogen (BIIB) up 51% after announcing its Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, met its primary endpoint and all key secondary endpoints
- Eli Lilly (LLY) and MorphoSys (MOR) up 8% and 16%, respectively, after Biogen's Clarity AD clinical trial results
- Ocugen (OCGN) up 12% after entering into an exclusive license agreement with Washington University in St. Louis for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered COVID-19 vaccine in the U.S., Europe, and Japan
UP AFTER EARNINGS -
- Thor Industries (THO) up 5%
DOWN AFTER EARNINGS -
- Cognyte (CGNT) down 9%
- BlackBerry (BB) down 4%
LOWER -
- Apple (AAPL) down 2% after Bloomberg reported Apple has told suppliers to back off from efforts to increase supply of iPhone 14 models by about 6M units in the second half of the year, and the company is now aiming to produce 90M units for the period
- Mind Medicines (MNMD) down 51% after a 7.06M share secondary offering priced at $4.25
- Lyft (LYFT) down 1% after New York Post reported that the company is freezing all hiring in the U.S. until the end of 2022 in response to the economic downturn and the company's stock slump
- Lockheed Martin (LMT) down 1% after Wells Fargo analyst Matthew Akers downgraded the stock to Underweight with a price target of $415
Symbols:
BIIB - $197.75 /
+1.985 (+1.01%)
LLY - $311.13 /
+2.875 (+0.93%)
MOR OCGN THO CGNT BB AAPL MNMD LYFT LMT - $399.63 /
-8.185 (-2.01%)
Keywords: Fly Intel, Wall Street, Top Stories, Stocks